Search results
Results from the WOW.Com Content Network
Inflammatory myofibroblastic tumor was initially regarded as a benign tumor that most often developed in the lung and less commonly in almost any organ system or tissue. Over time, however, IMT cases occurred in which the tumor spread into local tissues, metastasized to distal tissues, recurred after treatment, or consisted of neoplastic cells ...
It is a benign, small tumor located in the skin of the distal areas of the legs and, less commonly, the arm; it has occurred mostly in females. EWSR1-SMAD3-positive fibroblastic tumor was named based on the finding that its tumor cells express a EWSR1-SMAD3 fusion gene. Since its initial description in 2018, a total of 15 cases have been ...
Low-grade myofibroblastic sarcoma (LGMS) is a subtype of the malignant sarcomas. [1] As it is currently recognized, LGMS was first described as a rare, atypical myofibroblastic tumor (i.e. a tumor consisting of cells with the microscopic features of fibroblasts and smooth muscle cells) by Mentzel et al. in 1998. [2]
Plexiform angiomyxoid myofibroblastic tumor (PAMT), also called plexiform angiomyxoma, [1] plexiform angiomyxoid tumor, [2] or myxofibroma, [3] is an extremely rare benign mesenchymal myxoid tumor along the gastrointestinal tract. Most of PAMTs occur in the gastric antral region, but they can be situated anywhere in the stomach.
Uncommonly, these tumors have recurred at the site of their removal, particularly in cases where a portion of the original tumor was not removed. [5] Recurrences have occurred 4-120 months after the original resections [4] and have been treated by a second surgical resection. [2] Overall, AFST tumors have a good prognosis. [4]
UPS is a diagnosis of exclusion (a diagnosis reached by the process of elimination) because the histopathology of this disorder's tumors is non-specific. UPS tumor cells are undifferentiated (i.e. do not resemble any particular cell type) and pleomorphic (i.e. highly variable in size, shape, and/or color) when examined microscopically.
In 2020, the World Health Organization reclassified MFS as a separate and distinct tumor [4] in the category of malignant fibroblastic and myofibroblastic tumors. [5] MFS tumors are often treated by surgical resection. However, these tumors have high recurrence rates at the sites of their resections. [6]
NF may resemble and therefore be misdiagnosed as dermatofibrosarcoma protuberans, fibrosarcoma, malignant fibrous histiocytoma, spindle-cell melanoma, [27] leiomyosarcoma, [4] or inflammatory myofibroblastic tumor. [8] The diagnosis of NF and its variants depends on a combination of findings, no single one of which is definitive.